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Abstract
Background: There are three turkey b-adrenoceptors: the original turkey b-adrenoceptor from erythrocytes (tbtrunc, for
which the X-ray crystal structure has recently been determined), tb3C and tb4C-receptors. This study examined the
similarities and differences between these avian receptors and mammalian receptors with regards to binding characteristics
and functional high and low affinity agonist conformations.
Methodology/Principal Findings: Stable cell lines were constructed with each of the turkey b-adrenoceptors and
3H-
CGP12177 whole cell binding, CRE-SPAP production and
3H-cAMP accumulation assays performed. It was confirmed that
the three turkey b-adrenoceptors are distinct from each other in terms of amino acid sequence and binding characteristics.
The greatest similarity of any of the turkey b-adrenoceptors to human b-adrenoceptors is between the turkey b3C-receptor
and the human b2-adrenoceptor. There are pharmacologically distinct differences between the binding of ligands for the
tbtrunc and tb4C and the human b-adrenoceptors (e.g. with CGP20712A and ICI118551). The tbtrunc and tb4C-
adrenoceptors appear to exist in at least two different agonist conformations in a similar manner to that seen at both the
human and rat b1-adrenoceptor and human b3-adrenoceptors. The tb3C-receptor, similar to the human b2-adrenoceptor,
does not, at least so far, appear to exist in more than one agonist conformation.
Conclusions/Significance: There are several similarities, but also several important differences, between the recently
crystallised turkey b-adrenoceptor and the human b-adrenoceptors. These findings are important for those the field of drug
discovery using the recently structural information from crystallised receptors to aid drug design. Furthermore, comparison
of the amino-acid sequence for the turkey and human adrenoceptors may therefore shed more light on the residues
involved in the existence of the secondary b-adrenoceptor conformation.
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Introduction
There are three human b-adrenoceptors, b1, b2 and b3 and all
are Gs-coupled GPCRs. Following observations by Pak and
Fishman [1], recent studies from several groups (including this
laboratory) have suggested that the human b1-adrenoceptor [2–
13] and b3-adrenoceptor [14], so far in contrast to the b2-
adrenoceptor, exist in two agonist states or conformations. The
high affinity ‘‘catecholamine’’ conformation is where catechol-
amines and many other agonists act and these agonist responses
are readily inhibited by b-blockers. Agonist responses are also seen
via stimulation of the secondary or lower affinity conformation but
these agonist responses require significantly higher concentrations
of antagonist to be inhibited [2–14]. Ligands have also been found
to have different efficacies at the two conformations with some
ligands being agonists of both conformations (e.g. alprenolol,
pindolol; [10], including work from this laboratory [11]), others
acting as antagonists at both sites (albeit with markedly different
affinities e.g. CGP20712A, bisoprolol; [6–7], including previous
studies from this laboratory [9]) and others acting as antagonists at
the high affinity site whilst stimulating an agonist response via the
lower affinity site (i.e. at higher concentration of ligand e.g.
CGP12177 carvedilol; [6] [11–12]. The precise nature of this
second conformation however remains uncertain. It appears that,
at least for the human b1-adrenoceptor, some of the same residues
are required by both conformations of the receptor and therefore
the binding site for the classical catecholamine site and the
secondary site must overlap to some degree [13].
The turkey has a b-adrenoceptor expressed on erythocytes that
has been studied for many years [15–18]. However Nicholas and
colleagues identified two further turkey b-adrenoceptors, the
turkey b3C and turkey b4C-adrenoceptors [19]. They conclude
that the turkey b4C-adrenoceptor is distinct both in amino-acid
sequence and pharmacological characteristics from the original
turkey b-adrenoceptor. They also mention a turkey b3C-
adrenoceptor that appears similar to the mammalian b2-
adrenoceptor, although its sequence and pharmacological char-
acterisation are not presented. It is not known whether these avian
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15487receptors exist in one or more agonist conformations or how
pharmacologically similar they are, or not, to the human b-
adrenoceptors. Knowledge of more active agonist conformations
may assist in determining which other residues in the human
receptors are necessary for this property.
The X-ray crystal structure has recently been determined for
the human b2-adrenoceptor and the original turkey b-adreno-
ceptor [20–23]. This is potentially of huge importance for those in
the field of drug discovery who are using computational models of
these receptors to assist in the process of ligand design. An
important question is how similar, if at all, is the pharmacology of
the original turkey b-adrenoceptors to any of the human b-
adrenoceptors.
Thus there are two important reasons to understand the
detailed pharmacological properties of the three turkey b-
adrenoceptors: 1) to understand the similarities and differences
between the human and the original turkey b-adrenoceptor (where
structural information in now available) to understand how best to
use this information in the field of drug design and 2) to investigate
whether any of these have more than one active agonist
conformation and so understand more about the residues involved
that give some b-adrenoceptors the high and low affinity states.
This study therefore examines in detail the pharmacology of the
three turkey b-adrenoceptors, firstly to determine their pharma-
cological similarity to each other, then the similarity to the three
human b-adrenoceptors and finally to determine whether or not
they exist in more than one active agonist conformation.
Methods
Materials
Foetal calf serum which was from PAA Laboratories (Tedding-
ton, Middlesex, UK). Microscint 20 scintillation fluid from
PerkinElmer (Shelton, CT, USA).
3H-CGP12177,
3H-adenine
and
14C-cAMP were from Amersham International (Buckingham-
shire, UK). Betaxolol, bisoprolol, bucindolol, BRL37344, carve-
dilol, cimaterol, formoterol, ICI215001, isoprenaline, L755507,
salmeterol, SDZ21009, SR59230A, ZD2079 and ZD7114 were
from Tocris Life Sciences (Avonmouth, UK). Carazolol was a gift
from Dr Christopher Tate (LMB, Cambridge, UK); nebivolol and
butoxamine were a gift from Stefano Evangelista (Menarini
Ricerche Spa, Florence, Italy); zinterol was a gift from Dr Torsten
Christ (Department of Pharmacology and Toxicology, Dresden
University of Technology, Germany.). All other reagents were
from Sigma Chemicals (Poole, Dorset, UK).
Cell lines and cell culture
CHO-K1 stably expressing a CRE-SPAP (secreted placental
alkaline phosphatase) reporter gene [24] were secondarily
transfected with either the original full length turkey b-adreno-
ceptor, the turkey b3C-adrenoeptor or the turkey b4C-adreno-
ceptor (all gifts from Dr Rob Nicholas, University of North
Carolina, USA; all on geneticin selection marker) using Lipofec-
tamine and OPTIMEM as per manufacturer’s instructions.
Despite multiple efforts the original full length turkey b-
adrenoceptor did not express. A C-terminally truncated version
was therefore transfected (tbtrunc, gift from Dr Chris Tate, LMB,
Cambridge, UK). This mutant has 59 amino-acids deleted from
the C-terminus and one point mutation C116L [23]. For transient
transfections (initial binding experiments only, see Results), the
parent CHO-SPAP cells were transfected on day 1, the
transfection reagents removed and replaced with media on day
2, the cells plated in to white-sided 96 well plates on day 3 and a
binding assay performed on day 4. To generate stable cells lines (as
used for all the binding and functional data presented in this
manuscript), cells were selected for 3 weeks using resistance to
geneticin (1 mg/ml for the receptor) and hygromycin (200 mg/ml
for the CRE-SPAP reporter). Single clones were then isolated by
dilution cloning. Cells were grown in Dulbecco’s modified Eagle’s
medium nutrient mix F12 (DMEM/F12) containing 10% foetal
calf serum and 2 mM L-glutamine in a 37uC humidified 5% CO2:
95% air atmosphere.
3H-CGP12177 Whole Cell Binding
Cells were grown to confluence in white-sided tissue culture
treated 96-well view plates.
3H-CGP12177 whole cell binding was
performed as previously described [25]. For saturation binding,
the media was removed from each well, then 100 ml serum-free
media (DMEM/F12 containing 2 nM L-glutamine) or 100 ml
propranolol 20 mM added to each well.
3H-CGP 12177 (in 100 ml,
thus a 1:2 dilution in the well, to give final well concentrations of
0.02 nM to 25.84 nM for
3H-CGP12177 and 10 mM propranolol
to define non-specific binding) was added immediately and the
plates incubated for 2 hours at 37uC, 5% CO2, humidified
atmosphere. For competition binding, the media was removed
from each well, 100 ml of serum-free media containing the
competing ligand at twice the final required concentration was
added to each well followed immediately by a 100 ml of a fixed
concentration of
3H-CGP12177 (1:2 dilution in well, final well
concentrations of 1.24 nM to 12.10 nM). The cells were incubated
for 2 hours at 37uC, 5% CO2 humidified atmosphere. For all
plates, the cells were washed twice by the addition and removal of
200 ml4 uC phosphate buffered saline. 100 ml Microscint 20 was
added to each well, a white sticky base applied to the underside
and a sealant top applied to the top of the plate. The plates were
left at room temperature overnight in the dark and the plates
counted on a Topcount at 21uC for 2 minutes per well.
CRE-SPAP production
Cells were grown to confluence in clear plastic tissue culture
treated 96-well plates. The cells were then serum starved for
24 hours before experimentation by removal of the media and
addition of 100 ml serum free media per well. At the start of each
experiment, 100 ml serum free media or 100 ml serum free media
containing an antagonist at the final required concentration was
added to the wells and the cells incubated for 30 minutes at 37uC.
Agonist in 10 ml was then added to each well and the plates
incubated for 5 hours. After 5 hours, the media and all drug were
removed from each well and 40 ml serum free media added to
each well. The plates were then incubated for 1 hour at 37uC. The
plates were then transferred to an oven preheated to 65uC and
incubated for 30 minutes to destroy endogenous phosphatases.
SPAP production was then measured by the addition of 100 ml
5 mM p-NPP per well (in diethanolamine buffer) and read on a
Dynatech MRX plate reader at 405 nM.
3H-cAMP accumulation
Cells were grown to confluence in clear plastic tissue culture
treated 24-well plates. The media was removed and the cells pre-
labelled with
3H-adenine by incubation for 2 hours with 2 mCi/ml
3H-adenine in serum-free media (0.5 ml per well). The
3H-adenine
was removed and each well washed by the addition and removal of
1 ml serum-free media. 1 ml serum-free media containing 1 mM
IBMX was added to each well and the cells incubated for 15
minutes. Agonists (in 10 ml serum-free media) were added to each
well and the plates incubated for 5 hours. Where CGP 12177 and
cimaterol were co-incubated with the cells, the two ligands were
added together after the 15 minute IBMX incubation. The reaction
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PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e15487Figure 1. The amino acid sequence of the three turkey and the three human b-adrenoceptors. Amino acid sequences shown for
published receptors are taken from UniProtKB/Swiss-Prot and correspond to the translation of the coding sequence from each nucleotide receptor
construct used in the present study. All receptor constructs were checked by sequencing on both strands using automated fluorescent sequencing
(University of Nottingham, Nottingham, U.K.).
doi:10.1371/journal.pone.0015487.g001
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The plates were then frozen, thawed and
3H-cAMP separated from
other
3H-nucleotides by sequential Dowex and alumina column
chromatography, as previously described [26].
Data analysis
Whole cell binding - Saturation binding. Saturation
binding curves of the total and non-specific binding (as
determined by the presence of 10 mM propranolol) were
performed in order to determine the specific binding KD value
for
3H-CGP12177 and the receptor expression level. All data
points on each binding curve were performed in quadruplicate.
Specific binding (SB, equation 1) of
3H-CGP12177 at different
concentrations of the
3H-ligand was fitted using the non-linear
regression program Prism 2.01 to the equation:
SB~
AxBMAX ðÞ
AzKD ðÞ
ð1Þ
where A is the concentration of
3H-CGP12177, BMAX is the
maximal specific binding and KD is the dissociation constant of
3H-CGP12177. Protein was determined by using a Pierce BCA
Protein Assay Kit (Thermo Scientific, Rockford, USA) as per
manufacturers’ instructions.
Whole cell binding - Competition binding. All data points
on each binding curve were performed in triplicate and each 96-
well plate also contained 3–6 determinations of total and non-
specific binding. In all cases where a KD value is stated, the
competing ligand completely inhibited the specific binding of
3H-
CGP12177.
A one-site sigmoidal response curve was then fitted to the data
using Graphpad Prism 2.01 and the IC50 was then determined as
the concentration required to inhibit 50% of the specific binding.
% of uninhibited binding~100{
100xA ðÞ
AzIC50
zNS ð2Þ
where A in the concentration of the competing ligand, IC50 is the
concentration at which half of the specific binding of
3H-
CGP12177 has been inhibited, and NS is the non-specific binding.
From the IC50 value and the known concentration of
radioligand [
3H-CGP12177], a KD (concentration at which half
the receptors are bound by the competing ligand) value was
calculated using the equation:
KD~
IC50
1z 3H{CGP12177 ½  =KD
3H{CGP12177 ðÞ
ð3Þ
Functional assays - 3H-cAMP accumulation and CRE-
SPAP production. Most agonist responses were best described
by a one-site sigmoidal concentration response curve (equation 4)
Response~
EMAX xA ½ 
EC50z A ½ 
ð4Þ
Where Emax is the maximum response, [A] is the agonist
concentration and EC50 is the concentration of agonist that
produces 50% of the maximal response
The affinities of antagonists were calculated (KD values) from
the shift of the agonist concentration responses in the presence of a
fixed concentration of antagonist using equation 5:
Figure 2. Inhibition of
3H-CGP12177 specific binding to whole
cells expressing the 3 turkey b-adrenoceptors. Inhibition of
3H-
CGP12177 specific binding to whole cells by CGP20712A and ICI118551
in a) CHO tbtrunc cells, b) CHO tb3C cells and c) CHO tb4C cells. Non-
specific binding was determined by 10 mM propranolol. The concen-
trations of
3H-CGP 12177 present in each case are a) 1.24 nM, b)
0.855 nM and c) 1.59 nM. Data points are mean 6 s.e.mean of triplicate
determinations. These single experiments are representative of a) 5, b) 9
and c) 9 separate experiments.
doi:10.1371/journal.pone.0015487.g002
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3H-CGP 12177 whole cell binding studies at the three turkey b-adrenoceptors.
tbtrunc tb3C tb4C Human b1 Human b2 Human b3
Acebutolol 25.8560.02 6 25.3960.09 10 25.4160.08 6 26.46 26.08 24.41
Adrenaline 26.0160.04 6 25.8160.06 9 25.7760.08 7 25.15 26.13 24.70
Alprenolol 27.9660.04 5 28.4460.10 7 27.8560.10 7 27.83 29.04 26.93
Atenolol 25.4060.06 6 24.7560.10 10 24.7660.05 7 26.66 25.99 24.11
Betaxalol 26.9060.04 6 26.2960.08 8 26.2460.06 7 28.21 27.38 25.97
BRL35135A 26.3260.07 5 27.4260.06 5 26.3960.03 5 26.08 27.38 26.73
BRL37344 25.1960.03 6 26.2860.06 7 25.8960.10 7 25.19 26.51 26.45
Bisoprolol 26.7060.03 6 25.5860.08 6 26.2660.08 7 27.83 26.70 25.67
Bupranolol 28.4360.04 6 29.0760.07 7 28.1860.09 7 28.51 29.85 27.04
Bucindolol 29.4360.06 7 29.7260.09 9 29.4160.07 6 29.31 29.99 28.04
Butoxamine 25.2460.03 6 25.9960.08 6 24.9060.05 4 24.85 26.23 .24
Carazolol 210.2060.05 6 210.9260.11 6 210.2760.09 6 29.69 210.49 28.35
Carvedilol 29.4360.05 5 29.5860.07 7 29.9160.02 7 28.75 29.40 28.30
CGP20712A 27.5360.04 8 25.4060.11 9 26.0560.07 12 28.81 26.11 25.19
Cimaterol 27.1760.03 9 27.0660.08 8 26.7560.04 8 26.57 27.26 25.28
CL316243 .246 .244 .244 .23 24.10 25.11
Clenbuterol 26.7460.07 6 27.3860.10 7 26.4460.03 7 26.62 27.90 25.35
S-Cyanopindolol 210.8960.06 6 211.3760.07 6 210.8160.09 6 210.39 211.09 28.36
Denopamine 26.2960.05 7 25.6360.06 6 25.9560.03 6 26.12 25.83 25.30
Dobutamine 25.6960.03 6 25.5760.06 8 26.0060.06 7 25.23 25.84 25.09
Fenoterol 26.3660.03 6 26.6960.07 10 26.2260.10 10 25.04 27.03 25.39
Formoterol 27.3360.06 6 27.9660.07 7 27.7060.07 7 26.11 28.63 25.82
ICI118551 27.2060.03 5 28.9360.06 9 27.3760.03 9 26.52 29.26 26.44
ICI215001 25.7960.05 6 25.3160.09 7 26.5560.06 10 26.37 25.86 26.63
Isoprenaline 26.8660.08 7 26.5060.08 7 26.7160.09 7 26.06 26.64 25.52
Labetolol 27.5160.05 6 27.4260.04 7 27.7060.04 6 27.63 28.03 26.18
L755507 27.1760.03 7 26.5660.06 5 27.6360.11 5 26.23 26.83 28.60*
Metaproterenol 25.6460.07 6 25.3860.09 5 25.1360.09 6 24.71 25.30 24.06
Metoprolol 26.4260.03 7 25.9660.09 6 25.7860.07 7 27.26 26.89 25.16
Nadolol 27.9960.04 6 27.9560.09 6 27.7460.03 6 27.23 28.60 26.18
Noradrenaline 26.6060.03 6 24.9460.07 7 26.3060.08 7 25.74 25.41 25.53
Nebivolol 28.2560.05 6 27.7860.09 8 28.8360.08 9 29.06 27.92 27.04
Pindolol 28.5560.03 6 28.7160.10 8 28.2860.06 7 28.57 29.23 27.08
Pronethalol 26.8560.01 6 26.9960.07 7 27.0660.04 7 26.44 27.36 25.89
Propranolol 28.5160.05 7 28.4960.06 7 28.5160.06 7 28.16 29.08 26.93
Ractopamine 26.7560.03 6 26.6560.04 6 26.5760.04 6 26.97 26.93 25.82
Salbutamol 24.9960.03 6 26.1460.07 7 25.3660.05 7 24.66 26.12 24.33
Salmeterol 25.9260.04 8 28.5060.07 8 27.0960.04 8 25.73 29.26 26.33
SDZ21009 29.2760.08 6 210.1760.08 10 29.0660.07 7 28.94 210.28 27.10
SR59230A 27.3960.04 7 27.9660.08 6 27.6560.06 7 27.54 28.45 27.37
Sotalol 26.1460.06 6 26.2760.08 6 26.1660.05 7 25.77 26.85 25.05
Terbutaline 24.6160.04 6 25.6260.09 10 24.4760.05 5 23.82 25.62 23.90
Timolol 28.7660.02 5 29.2460.10 11 28.7060.06 7 28.27 29.68 26.80
Tulobuterol 25.6060.06 7 26.6460.08 9 25.4660.04 7 25.62 26.83 24.72
Xamoterol 26.5860.02 6 25.6460.09 8 26.2360.05 7 27.22 26.07 24.45
ZD2079 23.7760.03 4 .244 .244 24.21 .24 24.59
ZD7114 27.3060.09 6 26.5960.10 7 27.5960.04 7 27.58 27.31 26.78
zinterol 26.4060.03 6 27.6260.08 6 26.8060.03 6 25.96 28.04 26.27
Log KD values obtained from
3H-CGP 12177 whole cell binding studies in CHO cells stably expressing either the tbtrunc, tb3C or tb4C adrenoceptors. The human b1 b2
and b3-data is taken from [25] and [30] and is given for comparison. Values represent mean 6 s.e.m. for n separate experiments.
*binding to site 1 [30].
doi:10.1371/journal.pone.0015487.t001
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B ½ 
KD
ð5Þ
where DR (dose ratio) is the ratio of the agonist concentration
required to stimulate an identical response in the presence and
absence of a fixed concentration of antagonist [B].
In experiments where 3 different fixed concentrations of the
same antagonist were used, Schild plots were constructed using the
following equation 6:
log DR{1 ðÞ ~log B ½  {log KD ðÞ ð 6Þ
These points were then fitted to a straight line. A slope of 1 then
indicates competitive antagonism [27].
When CGP12177 was used to antagonise the more efficacious
agonists,clearpartialagonismwasseen.Here,theaffinitywasinitially
calculated by the method of Stephenson [28] using equation 7:
KD partial agonist~
YxP ½ 
1{Y
where Y~
A2 ½  { A1 ½ 
A3
ð7Þ
where [P] in the concentration of CGP12177, [A1]i nt h e
concentration of the agonist at the point where CGP 12177 alone
agonist causes the same response, [A2] is the concentration of agonist
causing a given response above that achieved by the partial agonist
and [A3] the concentration of the agonist, in the presence
CGP12177, causing the same stimulation as [A2].
Several of the responses were however best fitted to a two-site
concentration response – equation 8
%maximal stimulation~
A ½  xN
A ½  zEC150 ðÞ
z
A ½  x 100{N ðÞ
A ½  zEC250 ðÞ
ð8Þ
where N is the percentage of site 1, [A] is the concentration of
agonist and EC150 and EC250 are the respective EC50 values for
the two agonist sites.
A two-site analysis was also used for some experiments equation 9:
Response ~
Basalz Ag{Basal ðÞ 1{
P ½ 
P ½  zIC50 ðÞ

z PAg
P ½ 
P ½  zEC50 ðÞ
 ð9Þ
where basal is the response in the absence of agonist, Ag is the
response to a fixed concentration of agonist, [P] is the concentration
of partial agonist (e.g. CGP12177), IC50 is the concentration of
competing partial agonist that inhibits 50% of the response of the
fixed agonist, PAg is the maximum stimulation by the competing
partial agonist and EC50 is the concentration of competing agonist
that stimulated a half maximal competing partial agonist response.
A1 0mM (maximal) isoprenaline concentration was included
in each plate for each separate experiment for CRE-SPAP
production and
3H-cAMP accumulation, to allow agonist
Figure 3. Correlation plot of the log KD values for the turkey b-
adrenoceptors compared with each other. Ligands are labelled as
full agonists if the stimulated more than 90% of the response at the
human b1-adrenoceptor, as partial agonists if they stimulated 5–90% of
the full response and as antagonists if they stimulated less than 5% of a
full agonist response (data from human b1 taken from [9] [30] [39].
doi:10.1371/journal.pone.0015487.g003
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PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e15487Figure 4. Correlation plot of the log KD values for the turkey b-adrenoceptors compared with the human b-adrenoceptors.
Correlation plot of the log KD values for the ligands in Table 1 for the three turkey b-adrenoceptors vs the three human b-adrenoceptors. The human
adrenoceptor data is taken from [25] and [30]. Ligands are labelled as full agonists if the stimulated more than 90% of the response at the human b1-
adrenoceptor, as partial agonists if they stimulated 5–90% of the full response and as antagonists if they stimulated less than 5% of a full agonist
response (data from human b1 taken from [9] [30] [39].
doi:10.1371/journal.pone.0015487.g004
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maximum for each experiment. All data are presented as mean 6
s.e.m. of triplicate determinations (except saturation binding
experiments where determinations were from quadruplicate wells)
and n in the text refers to the number of separate experiments.
Results
The amino acid sequence of the three turkey b-adrenoceptors
and the three human b-adrenoceptors is given in Figure 1.
3H-CGP12177 whole cell binding
Binding studies were performed on both transiently transfected
cells and the stable cell lines to ensure that the stable cell line was
indeed a true reflection of the pharmacology of the transfected b-
adrenoceptor and that no alteration of the receptor had taken
place during the process of making the cell line. The results from 8
separate transiently transfected cell populations (both KD of
3H-
CGP12177 from saturation studies and KD values of betaxolol,
bisoprolol, clenbuterol, CGP20712A, formoterol, ICI118551,
metoprolol and xamoterol from competition studies) were very
similar to the results obtained from the stable cell line so only the
stable cell line data are presented here.
3H-CGP12177 bound specifically to all three turkey b-
adrenoceptors to give KD values of 0.4260.03 nM (n=12) for
the tbtrunc (receptor expression level of 148fmol/mg protein),
0.2960.02 nM (n=7) for the tb3C (63fmol/mg protein) and
0.5860.06 nM (n=7) for the tb4C-receptor (67fmol/mg protein)
Figure 5. CRE-SPAP production in response to cimaterol in the turkey b-adrenoceptors. CRE-SPAP production in response to cimaterol in
a) CHO tbtrunc cells, b) CHO tb3C cells and c) CHO tb4C cells in the absence and presence of propranolol. Bars represent basal CRE-SPAP production,
that in response to 10 mM isoprenaline and that in response to 10 nM or 30 nM, 100 nM or 300 nM, or 1000 nM or 3000 nM propranolol alone. Data
points are mean 6 s.e.mean of triplicate determinations. These single experiments are representative of 3 separate experiments in each case. The
Schild slopes in these experiments are a)1.10, b)1.15 and c)1.19.
doi:10.1371/journal.pone.0015487.g005
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ligands (including agonists, partial agonists and inverse agonists)
was then assessed. CGP20712A is a highly selective human b1-
antagonist (log KD at human b1=28.81; at human b2=26.11
[25]) and ICI118551 is a highly selective human b2-antagonist (log
KD at human b1=26.52; at human b2=29.26 [25]). However,
these ligands bind with almost equal affinity to the tbtrunc-
receptor (27.53 for CGP20712A and 27.20 for ICI118551;
Figure 2, Table 1). ICI118551 however has high affinity, and
CGP20712A low affinity, for the tb3C-receptor in a similar
pattern to that of the human b2-adrenoceptor.
When many ligands are examined it is possible to build up a
pattern of affinities and thus judge the similarity or differences
between the receptors (Table 1, Figure 3). For comparative
purposes, the equivalent binding affinity plot comparisons between
the human b-adrenoceptors are given in the Figure S1.
Similarly, the turkey b-adrenoceptors can be compared to the
human b-adrenoceptors (Table 1, Figure 4). From this is can be
seen that the greatest similarity is between the tb3C-receptor and
the human b2-adrenoceptor.
CRE-SPAP gene transcription
Isoprenaline stimulated CRE-SPAP gene transcription respons-
es that were 2.3460.10 (n=10), 2.3060.09 (n=19) and
2.4760.10 (n=22) fold over basal for tbtrunc, tb3C and tb4C-
receptors respectively. The agonist activity of 10 other b-
adrenoceptor agonists and CGP12177 was also studied. These
agonist responses were then inhibited by the non-selective b-
antagonist propranolol, the human b1-selective antagonist
CGP20712A and the human b2-selective antagonist ICI118551
(Figure 5 Tables 2–4). At the tb3C-receptor there is a range of
antagonist KD values seen for all three antagonists (e.g. for
propranolol, the KD values range from 29.01 to28.78 when the
non-catecholamine agonists are present and 28.45 to 28.13 for
when the catecholamines are the competing agonist). This is very
similar to that previously reported from the human b2-
adrenoceptor in this assay [29]. The KD value for propranolol
when CGP12177 is that agonist it 28.95, very similar to that for
when the other the non-catecholamine agonists are present. The
same pattern is true for CGP20712A and ICI118551. At the
tbtrunc and tb4C-receptors, a similar range in antagonist KD
values is seen for when the non-catecholamine and catecholamine
agonists are present (again the KD values are lower in the presence
of the catecholamines, similar to that in [9,14]). However, at the
tbtrunc and tb4C-receptors, the concentrations of antagonist
required to inhibit the CGP12177 agonist response were
significantly higher than the concentrations required to inhibit
any the other agonist responses (Figure 6 Tables 2–4).
The antagonistic ability of CGP12177 itself was then investi-
gated and was found to be a high affinity partial agonist at all three
turkey b-adrenoceptors (Figure 7, Tables 2–4).
Looking carefully at the CGP12177 concentration response curve,
this might not be best described by a one-site sigmoidal concentration
response curve in all cases (Figure 6). This was therefore investigated
furtherinanassaywithamuchlargerbasaltomaximumwindow(see
b e l o w )w h e r et h e s es m a l l e rd e t a i l sa r em o r ee a s i l ys e e n .
3H-cAMP accumulation
S-cyanopindolol was the ligand with which the tbtrunc-receptor
X-ray structure was originally solved [23]. It stimulates a two-
component concentration response curve at the human b1 and
b3-adrenoceptors, but only a one-component sigmoidal concen-
tration response at the human b2-adrenoceptor [30]. The agonist
action of this compound was therefore investigated at the three
turkey b-adrenoceptors. The
3H-cAMP assay was chosen for this
as it has a much bigger window (basal to maximum) in which to
examine small responses in detail.
S-cyanopindolol was found to be a partial agonist at all three
turkey b-adrenoceptors and stimulated an agonist response that
was best described by a two component response at both the
tbtrunc and tb4C-receptors, but a one-component response at the
tb3C-receptor (Figure 8, Table 5).
In this assay with a bigger response window, CGP12177
stimulated an agonist response that was also best described by a
two-component response for both the tbtrunc and tb4C-receptors
(Figure 9, Table 5). This is in contrast to the findings at the human
b1a n db3-adrenoceptors (where even in assays with a large
experimental window, the CGP 12177 response was best described
by a one-component concentration response curve). For the tb3C-
receptor, the CGP12177 agonist response was best described by a
Table 2. Agonist and antagonist characteristics at the truncated turkey b-adrenoceptor.
tbtrunc Log EC50 % isop max n
Log KD
propranolol n
Log KD
CGP20712A
Log KD
ICI118551 n
Log KD
CGP12177 n
fenoterol 28.1760.02 119.465.2 3 28.8460.05 9 28.2060.00 4 27.4360.05 5 29.6660.09 9
formoterol 28.9660.04 115.265.1 5 28.7760.03 10 28.2060.10 5 27.4460.09 6 29.6560.07 8
BRL37344 26.4560.05 107.964.2 8 28.7260.05 6 28.0460.07 75 27.2560.08 8 29.4460.11 11
cimaterol 28.6360.05 122.264.6 7 28.7060.05 9 28.2460.09 5 27.4960.04 6 29.5460.07 14
clenbuterol 27.6660.05 102.163.5 12 28.5260.05 16 27.8260.09 13 27.3260.10 12 29.4060.07 15
salmeterol 26.8660.05 112.262.9 13 28.4260.08 10 27.7160.08 11 27.1560.10 9 29.3260.10 9
salbutamol 26.3360.07 104.863.5 10 28.4160.10 10 27.9360.09 6 27.1960.08 6 29.3460.11 10
adrenaline 27.1360.08 117.263.1 8 28.3860.12 13 27.3560.12 9 26.8260.05 7 29.1960.06 8
noradrenaline 27.7460.04 113.064.2 12 28.3560.07 16 27.5160.08 11 26.9860.07 13 29.0560.10 11
isoprenaline 28.1160.12 100 10 28.2160.10 18 27.2560.13 8 26.7260.12 10 29.1960.11 12
dobutamine 26.5360.06 123.865.1 3 28.1960.11 9 27.5360.09 5 26.8060.09 4 28.9460.08 7
CGP12177 28.3860.08 53.163.6 20 27.2360.12 18 26.9160.15 12 26.3660.17 11
Log EC50 values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO tbtrunc cells. Log KD values for propranolol, CGP20712, ICI118551
and CGP12177 as antagonists of the agonist responses are also given. Values are mean 6 s.e.m. of n separate determinations.
doi:10.1371/journal.pone.0015487.t002
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human b2-adrenoceptor. In addition, at the tb3C-receptor,
CGP12177 behaved as a typical partial agonist, inhibiting cimaterol
at similar concentrations that cause a stimulatory effect, just as
would be expected when both ligands (CGP 12177 and cimaterol)
are competing at one single site (Figure 9b). At the tbtrunc and
tb4C-receptors, CGP12177 was initially (i.e. at low concentrations)
able to inhibit the response to cimaterol at similar concentrations to
that required when the first component of stimulation by CGP
12177 is seen. This would be consistent with cimaterol and CGP
12177 competing at the same (‘‘catecholamine’’) site of the receptor.
However, as the CGP 12177 concentration increases, the overall
stimulation by CGP 12177 increases as the second component of
the response is seen. This cannot be occurring at the same site as the
cimaterol response and first component of CGP 12177 response as
further addition of CGP 12177 would then make no difference in
overall stimulation (aka tb3C where CGP 12177 acts via one-site
only). This second component stimulation, to the right of the
cimaterol inhibition, must therefore be occurring at a different
agonist site on the receptors.
Parent CHO cells
There was no specific binding of
3H-CGP12177 to the parent
CHO cells (i.e. CHO cells without a transfected receptor). In the
3H-cAMP accumulation assay, the parent CHO cells responded to
forskolin (21.562.2 fold over basal, n=10) but there was no
response to the other ligands.
Discussion
Ligand binding has long been used to determining which
receptors are present in a given tissue [31]. A ligand binds to a
Table 4. Agonist and antagonist characteristics at the turkey b4C-adrenoceptor.
tb4C Log EC50
% isop
max n
Log KD
propranolol n
Log KD
CGP20712A
Log KD
ICI118551 n
Log KD
CGP12177 n
fenoterol 28.0760.05 99.963.0 20 28.5860.07 4 26.0160.06 6 27.3360.08 4 29.1060.11 10
formoterol 29.7860.06 96.364.5 21 28.5560.08 14 25.9060.03 6 27.2160.10 4 29.0460.06 8
BRL37344 27.1560.07 97.163.0 16 28.5460.05 4 26.0460.07 6 27.3360.08 4 29.0760.07 6
cimaterol 28.7060.05 98.262.3 18 28.5660.07 14 26.0060.09 5 27.2560.02 5 29.0260.09 12
clenbuterol 27.3960.06 97.261.9 21 28.3260.07 14 25.9760.05 6 27.1960.11 7 28.8460.09 13
salmeterol 28.4060.07 102.562.8 18 28.4060.11 5 25.9360.07 6 27.2760.11 5 28.9760.05 8
salbutamol 27.3760.05 99.962.3 20 28.4660.05 4 25.9460.03 6 27.3860.01 3 29.1360.08 9
adrenaline 26.7260.05 99.662.7 18 27.8360.09 14 25.6760.10 6 26.8360.09 7 28.8560.10 6
noradrenaline 27.0960.09 102.362.5 19 27.5960.13 13 25.7860.08 4 26.8260.09 3 28.5860.10 7
isoprenaline 27.8860.12 100 22 27.8760.13 13 25.7460.12 7 26.7260.12 5 28.8560.10 6
dobutamine 26.8060.09 110.462.4 18 27.9260.11 4 25.6360.08 4 26.5660.08 12 28.5860.09 9
CGP12177 27.8360.05 53.462.2 24 26.4760.09 15 25.3060.11 10 26.2060.06 12
Log EC50 values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO tb4C cells. Log KD values for propranolol, CGP20712, ICI118551 and
CGP12177 as antagonists of the agonist responses are also given. Values are mean 6 s.e.m. of n separate determinations.
doi:10.1371/journal.pone.0015487.t004
Table 3. Agonist and antagonist characteristics at the turkey b3C-adrenoceptor.
tb3C Log EC50 % isop max n
Log KD
propranolol n
Log KD
CGP20712A
Log KD
ICI118551 n
Log KD
CGP12177 n
fenoterol 29.0860.08 105.963.0 16 29.0160.04 4 25.6160.11 6 29.3460.07 4 29.9460.08 9
formoterol 210.3560.05 103.663.0 19 28.7860.05 14 25.4460.10 6 29.2960.06 5 29.7160.07 10
BRL37344 27.6760.04 88.564.2 16 29.0160.12 5 25.5160.12 7 29.3160.07 4 29.7360.11 7
cimaterol 29.3660.08 103.162.2 17 28.9360.08 13 25.4660.06 5 29.4060.06 4 29.5860.07 11
clenbuterol 29.2860.06 97.864.4 17 28.9560.06 13 25.7560.06 4 29.4760.05 4 29.7860.07 10
salmeterol 210.4360.06 96.065.7 18 28.9060.09 5 25.2060.12 8 29.2160.08 5 29.7660.11 7
salbutamol 28.4560.06 101.863.1 16 28.9060.07 4 25.4960.10 7 29.3160.09 4 29.7160.11 6
adrenaline 27.2060.09 105.962.7 17 28.2460.07 11 25.3460.09 6 28.7960.08 7 29.3760.08 10
noradrenaline 26.3860.07 101.863.0 20 28.4560.10 13 25.2860.11 5 28.8660.11 6 29.1860.10 9
isoprenaline 27.5760.09 100 19 28.1360.09 13 25.4360.10 4 28.6060.11 8 29.1160.11 11
dobutamine 26.3760.06 100.863.7 15 28.4560.09 4 25.1360.09 5 28.9460.09 4 29.0060.09 6
CGP12177 29.6660.06 39.963.2 19 28.9560.08 11 25.5760.15 8 29.5060.08 10
Log EC50 values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO tb3C cells. Log KD values for propranolol, CGP20712, ICI118551 and
CGP12177 as antagonists of the agonist responses are also given. Values are mean 6 s.e.m. of n separate determinations.
doi:10.1371/journal.pone.0015487.t003
Pharmacology of the Turkey b-Adrenoceptors
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e15487certain receptor with a given affinity and this affinity will remain
similar whichever tissue the receptor is expressed in. If a range of
ligands are examined, a pattern, similar to a fingerprint, is
obtained for a given receptor. Figure 3 shows the affinity of 48
ligands at the turkey receptors. Although the tbtrunc and tb4C-
receptors have distinct amino acid sequences, they are the most
pharmacologically similar of the turkey b-adrenoceptors. Thus the
turkey b-adrenoceptor [15] is distinct (in sequence and/or
binding) from either the turkey b3C or b4C-adrenoceptors [19]
as indeed the tb3C and tb4C-receptors are from each other. The
turkey therefore has three distinct b-adrenoceptors.
Figure 4 shows a comparison of the same 48 ligands with the
affinity for the human b1, b2 and b3-adrenoceptors. Here, it can
be seen that the turkey b3C-receptor has a similar affinity pattern
to that of the human b2-adrenoceptor. The affinity of ligands for
the tb-trunc and tb4C-receptor do not correlate as well with any of
the human b-adrenoceptors and thus the tbtrunc and tb4C are
distinct b-adrenoceptors. Figure 2 demonstrates this with two
individual ligands (CGP20712A and ICI118551) which are highly
selective for the human b1 and b2-adrenoceptors respectively.
Interestingly this species effect is seen elsewhere - ICI118551,
whilst having high affinity for the human b2-adrenoceptor has
lower affinity for the porcine b2-adrenoceptor [32–34].
The b1-adrenoceptor [2–13] (and human b3-adrenoceptor
[14]) have been shown to exist in two different conformations.
Agonist responses occurring at the high affinity catecholamine site
are blocked by traditional b-blockers whilst agonist responses
occurring via the secondary low affinity site are relatively resistant
to antagonism. The presence of both of these sites has been
reported in transfected cell systems (e.g. [1] [6] [35], including
work from this laboratory [9] [11], [14]), isolated cells (e.g. rat
cardiomyocytes, [36]), tissues (e.g. mouse brown fat [35] ferret
Figure 6. CRE-SPAP production in response to CGP 12177 in the turkey b-adrenoceptors. CRE-SPAP production in response to CGP12177
in a) CHO tbtrunc cells, b) CHO tb3C cells and c) CHO tb4C cells in the absence and presence of propranolol. Bars represent basal CRE-SPAP
production, that in response to 10 mM isoprenaline and that in response to propranolol (range 10 nM to 100 mM) alone. Data points are mean 6
s.e.mean of triplicate determinations. These single experiments are representative of 3 separate experiments in each case.
doi:10.1371/journal.pone.0015487.g006
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mice [38–39] and humans [40]). Several b-adrenoceptors have
been shown to activate different downstream signalling (‘‘dual
efficacy ligands’’ e.g. human b2 [41–42] and mouse b3 [43] but
this is different from the high affinity/low affinity states of the b1
and b3-adrenoceptors outlined above.
There are four lines of evidence for the existence of a secondary
low affinity or CGP12177 site on b-adrenoceptors from functional
assays. Firstly, the EC50 for the CGP12177 stimulatory response is
not the same as the CGP12177 KD value for antagonism of other
agonists [6,11]. If only one site is present on a receptor, the EC50
of a partial agonist (concentration at which half the response is
stimulated) is the same as the KD value (concentration at which
half of the receptors are occupied). A full, more efficacious agonist
would only need to occupy only a few receptors in order to elicit a
response, and thus the EC50 value will be lower than the KD value.
CGP12177 stimulated a partial agonist response at all three turkey
b-adrenoceptors. For the tb3C-receptors, the EC50 value for
CGP12177 (29.66) is within the range of KD values obtained from
antagonism of the more efficacious agonists (29.11 to 29.94)
suggesting that CGP12177 is a typical partial agonist causing its
stimulation and antagonism by occupying the same conformation
of the receptor (which is also the same conformation occupied by
the other agonists). This is similar to that reported for the human
b2-adrenoceptor [24]. However for the tbtrunc and tb4C-
receptors, CGP12177 has an EC50 value that was significantly
Figure 7. CRE-SPAP production in response to cimaterol in the turkey b-adrenoceptors. CRE-SPAP production in response to cimaterol in
a) CHO tbtrunc cells, b) CHO tb3C cells and c) CHO tb4C cells in the absence and presence of CGP12177. Bars represent basal CRE-SPAP production,
that in response to 10 mM isoprenaline and that in response to 1 nM, 10 nM, 100 nM or 1000 nM CGP12177 alone. Data points are mean 6 s.e.mean
of triplicate determinations. These single experiments are representative of a) 5, b) 4 and c) 5 separate experiments.
doi:10.1371/journal.pone.0015487.g007
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that reported for human and rat b1-adrenoceptors [6] [11]. This
would therefore suggest that for the tbtrunc and tb4C-receptors,
the CGP12177 stimulation is occurring at a different place
(requiring more ligand and so higher affinity) than when
CGP12177 is inhibiting the other agonists.
The second piece of pharmacological evidence for more than
one conformation is the concentrations of antagonists required to
inhibit the CGP12177-stimulatory response. If the CGP12177
partial agonist response was occurring at the same conformation as
the other agonist responses, they would require the same
concentrations of other antagonist to inhibit it (and thus the KD
value of other antagonists would be the same regardless of which
agonist was used). For the tb3C-receptor, the KD values of the
antagonists (propranolol, CGP20712A and ICI118551) are the
same for when CGP12177 is the agonist as to when the other 11
agonists are used (Table 3, also as for the human b2-adrenoceptor
[24]). However, the concentrations of propranolol, CGP20712A
and ICI118551 required to inhibit the CGP12177 response at the
tbtrunc and tb4C-receptors was significantly greater (leading to
lower KD values) than those required to inhibit the other 11
agonist responses (Tables 2 and 4). This is similar to observations
at the b1-adrenoceptor in rodents and mammals [6–7] [9] [11].
This would suggest that the CGP12177 agonist response was
occurring at a different pharmacological site to the other agonist
responses. There was no response to any ligands, including
CGP12177 in the parent CHO CRE-SPAP cells and thus the
CGP12177 agonist response was not occurring at a different
receptor natively expressed in the cells.
The third line of evidence comes from agonist response curves
that contain more than one component. Several ligands have been
previously shown to stimulate a two-component concentration
response curve at the b1-adrenoceptor (e.g. alprenolol, bucindolol,
carazolol, S-cyanopindolol, oxprenolol, pindolol, S-pindolol and
SDZ21009 [10–11] [30]. Several others have been shown to
stimulate a two component response at the human b3-adreno-
ceptor [14] [30] but to date none have been shown to stimulate a
similar two-component response at the human b2-adrenoceptor.
S-cyanopindolol stimulated an agonist response that was best
described by a two-component response at both the tbtrunc and
tb4C-receptors. The S-cyanopindolol response at the tb3C-
receptor is best described by a one-component response. This
therefore suggests that S-cyanopindolol is able to stimulate a
response at two agonist conformations of the tbtrunc and tb4C-
receptors. When the agonist response to CGP12177 was examined
in more detail in the cAMP assay (with a larger window to
examine the response) it can be seen that it too stimulates a
response best described by a two-component response at both the
tbtrunc and tb4C-receptors.
Finally, if the tbtrunc and tb4C-receptors do indeed exist in two
agonist conformations and CGP12177 is able to bind to both
conformations (the first ‘‘catecholamine’’ conformation with high
affinity and the secondary conformation with lower affinity), then
it should be possible to demonstrate inhibition of a more
efficacious catecholamine-site agonist at low concentrations of
CGP12177, separately from the second site stimulatory response
at higher concentrations of CGP12177 [1] [6] [9] [11] [14]. This
is exactly what is seen for both the tbtrunc and tb4C-receptors
(Figure 9a and c). This pattern is not seen for the tb3C-receptor,
where inhibition of the agonist by CGP12177 occurred at a similar
concentration as the stimulatory effect of CGP12177, suggesting
that the two are indeed occurring at the same site (Figure 9b).
Thus the tbtrunc and tb4C-receptors appear to exist in more
than one agonist conformation, similar to that seen at the human
and rat b1-adrenoceptor and the human b3-adrenoceptor [1] [6]
[9] [11] [14]. The tb3C-receptor appears to exist in only one
agonist conformation, similar to that for the human b2-
adrenoceptor [24]. Overall there are therefore several different
b-adrenoceptors: human b1, human b3, tbtrunc and tb4C-
adrenoceptors that are distinct b-adrenoceptors, as defined by
their binding characteristics and/or amino acid sequence, but that
all exist in at least two agonist conformations. The human b2 and
Figure 8.
3H-cAMP accumulation in response to cyanopindolol
in the turkey b-adrenoceptors.
3H-cAMP accumulation in response
to cyanopindolol in a) CHO tbtrunc cells, b) CHO tb3C cells and c) CHO
tb4C cells. Bars represent basal
3H-cAMP accumulation and that in
response to 10 mM isoprenaline. Data points are mean 6 s.e.mean of
triplicate determinations. These single experiments are representative
of a) 4, b) 5 and c) 5 separate experiments.
doi:10.1371/journal.pone.0015487.g008
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3H-cAMP accumulation in response to cimaterol and CGP 12177 in the turkey b-adrenoceptors.
3H-cAMP accumulation in
response to CGP12177 in a) CHO tbtrunc cells, b) CHO tb3C cells and c) CHO tb4C cells in the absence and presence of a fixed concentration of
cimaterol. Bars represent basal
3H-cAMP accumulation, that in response to 10 mM isoprenaline and that in response to 0.3 nM, 1 nM, 3 nM or 10 nM
cimaterol alone. Data points are mean 6 s.e.mean of triplicate determinations. These single experiments are representative of a) 4, b) 5 and c) 4
separate experiments.
doi:10.1371/journal.pone.0015487.g009
Table 5. Log EC50 values and % isoprenaline maximal responses obtained from
3H-cAMP accumulation in the three turkey b-
adrenoceptors.
receptor ligand Log EC501 Log EC502 % site 1 % isop max n
tbtrunc S-Cyanopindolol 210.8460.07 27.4160.04 65.961.5% 36.663.4 4
CGP12177 29.4660.11 27.4060.10 59.462.2% 42.762.6 4
tb3C S-Cyanopindolol 210.6060.13 100% 4.660.7 5
CGP12177 29.3860.16 100% 5.360.4 5
tb4C S-Cyanopindolol 29.8160.14 27.2060.20 44.462.0% 16.462.7 5
CGP12177 28.7360.12 26.5860.15 41.367.2% 17.460.7 4
Log EC50 values and % isoprenaline maximal responses obtained from
3H-cAMP accumulation in CHO tbtrunc cells, CHO tb3C cells and CHO tb4C cells. Where responses
were best described by a two-component response, Log EC501, log EC502 values, % of response that was occurring via site 1 and % isoprenaline of the overall response
are given. Values are mean 6 s.e.m. of n separate determinations.
doi:10.1371/journal.pone.0015487.t005
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appear to exist in only one agonist conformation. Comparison of
the amino-acid sequences of these receptors, and others already
known to exist in two conformations e.g. rat and ferret b1-
adrenoceptors [6–7], should therefore help in determining which
residues are required for the existence of the second conformation.
In conclusion, there are three distinct turkey b-adrenoceptors.
Of these the greatest similarity of any of the turkey b-
adrenoceptors to human b-adrenoceptors is between the turkey
b3C-receptor and the human b2-adrenoceptor. There are
pharmacologically distinct differences between the binding of
ligands for the tbtrunc and tb4C and the human b-adrenoceptors.
The tbtrunc and tb4C-adrenoceptors appear to exist in at least
two different agonist conformations in a similar manner to that
seen at both the human and rat b1-adrenoceptor and human b3-
adrenoceptors. The tb3C-receptor, similar to the human b2-
adrenoceptor, does not, at least so far, appear to exist in more than
one agonist conformation. Comparison of the amino-acid
sequence for the turkey and human adrenoceptors may therefore
shed more light on the residues involved in the existence of the
secondary b-adrenoceptor conformation.
Supporting Information
Figure S1 Correlation plot of the log KD values for the
human b-adrenoceptors compared with each other.
Correlation plot of the log KD values for the ligands in
Table 1 for a) human b1 vs human b2-adrenoceptor, b) b1v s
human b3-adrenoceptor and c) b2 vs human b3-adrenoceptor. -
Ligands are labelled as full agonists if the stimulated more than
90% of the response at the human b1-adrenoceptor, as partial
agonists if they stimulated 5–90% of the full response and as
antagonists if they stimulated less than 5% of a full agonist
response. Data are from [25] [30].
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